SHARE NOW
The announcement of the partnership between Title21 Health Solutions and Germfree Labs hints at another product launch in the pipeline, while revolutionizing decentralized manufacturing and reducing time-to-market for cell and gene therapies.
Title21 and Germfree have today announced a partnership, introducing a mobile manufacturing platform, powered by Title21’s proprietary digital operating system (OS).
The partnership aims to address complexities associated with traditional centralized manufacturing models, reducing the impact of manufacturing bottlenecks to streamline access to cell and gene therapies and reduce the time-to-market.
How are you enjoying this news article? Let us know your thoughts, here >>
Through the innovative decentralized model, the collaboration aims to realize a future whereby life-saving therapies transcend geographical boundaries, thus improving access regardless of location or circumstance.
“We are thrilled to join forces with Title21 Health Solutions in our mission to revolutionize cell and gene therapy manufacturing. Our commitment to state-of-the-art facility infrastructure aligns with Title21’s OS expertise, enabling decentralized manufacturing to reduce therapy costs and expand access,” explained Carol Houts, Chief Strategy Officer of Germfree Labs.
“At Title21 Health Solutions, we’ve always focused on delivering innovation and ensuring quality and regulatory compliance. Partnering with Germfree Labs allows us to extend our impact in the cell and gene therapy space. Together, we are building the future of patient-centred healthcare,” added Lynn Fischer, CEO of Title21 Health Solutions.
Both Carol and Lynn were joined by Najib Rehman, Digital Automation Lead at ATMPS, to discuss the intricacies of ‘Distributed and Point-of-Care Manufacturing – Pharmaceutical QMS Essentials Digital Systems’ at Advanced Therapies Week last year.
To watch the full series, ‘Delivering on the Promise of Cell and Gene Therapy Distributed and Point-of-Care Manufacturing’ hosted by Germfree, click here >>
As the two companies partner to launch a significant milestone in cell and gene therapy manufacturing through decentralized production, we’re looking forward to hearing more about subsequent product launches from the partnership.
Source: Title21 press release, received via email; featured image supplied and published with permission from Germfree.
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
More like this
20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry
Oxford Biomedica Acquires ABL Europe from Institut Mérieux
Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome
Discover more like this
